BeiGene Ltd. (BGNE) saw its shares surge 5.24% on Wednesday, outperforming the broader market, after the European Commission approved the company's cancer treatment TEVIMBRA (tislelizumab) for expanded use in the region.
The approval allows TEVIMBRA, in combination with chemotherapy, to be used as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The decision was based on positive results from two Phase 3 studies that demonstrated a statistically significant overall survival benefit for patients treated with TEVIMBRA plus chemotherapy.
Investors welcomed the regulatory approval, which expands the addressable market for BeiGene's cornerstone solid tumor therapy. The company highlighted the urgent need for effective treatment options in these cancer types, citing the poor prognosis for patients diagnosed with advanced gastric and esophageal cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.